• Aptevo Therapeutics Inc has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).

• A high-risk AML patient treated in Cohort 1 with a combination of chemotherapy plus APVO436 achieved a complete remission (CR) after one cycle of therapy.
• The chemotherapy regimen included the standard leukemia drugs Mitoxantrone, Etoposide, and Cytarabine.
• The patient tolerated treatment without evidence of over toxicity.
• Overexpression of CD123 is the hallmark of many forms of leukemia. Aptevo's lead proprietary drug candidate, APVO436, is a bispecific CD3xCD123 ADAPTIR designed to redirect the patient's immune system to destroy leukemia cells expressing the target CD123 molecule on their surface.
• Price Action: APVO shares are up 54.6% at $10.02 during the morning session on the last check Tuesday.